MedTrace Logo

CRUSHed vs. Uncrushed Prasugrel in STEMI Patients Undergoing PCI

NCT03296540 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 729

Last updated 2021-05-07

No results posted yet for this study

Summary

The studys evaluates the effect of prehospital administration of crushed tablets of Prasugrel loading dose (in addition to ASA and standard care) versus uncrushed tablets of Prasugrel loading dose on efficacy and safety as well as pharmacodynamics as measured by platelet reactivity using VerifyNow.

Conditions

Interventions

DRUG

Prasugrel (Crushed tablets)

loading dose of 6 crushed tablets 10mg Prasugrel

DRUG

Prasugrel (Integral tablets)

loading dose of 6 integral tablets of 10mg Prasugrel

Sponsors & Collaborators

  • MicroPort Orthopedics Inc.

    collaborator INDUSTRY

  • Daiichi Sankyo

    collaborator INDUSTRY

  • Research Maatschap Cardiologen Rotterdam Zuid

    collaborator OTHER

  • Maasstad Hospital

    lead OTHER

Principal Investigators

  • George Vlachojannis, MD, PhD · Maasstadziekenhuis

  • Pieter C Smits, MD, PhD · Maasstadziekenhuis

  • Nicolas van Mieghem, MD, PhD · Erasmus Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-28
Primary Completion
2021-05-01
Completion
2021-05-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03296540 on ClinicalTrials.gov